FPR1 and gastric cancer: The discovery that innate immune receptors (i.e., FPR1 in gastric cancer and TLR7 in lung cancer) might control PUFA metabolism, inflammation resolution, angiogenesis, and cancer opens new possibilities to be exploited for cancer treatment.